In a man over 50 with lower urinary tract symptoms from benign prostatic hyperplasia, when should I choose terazosin, alfuzosin, or finasteride based on prostate size, symptom severity, and blood‑pressure status?

Choosing Between Terazosin, Alfuzosin, or Finasteride for BPH

Start with an alpha-blocker (terazosin or alfuzosin) for immediate symptom relief, then add finasteride only if the prostate is enlarged (>30-40cc) or PSA is elevated.

---

Initial Treatment Selection

Alpha-blockers are first-line therapy for all men with bothersome BPH symptoms, regardless of prostate size 1, 2

• Alfuzosin provides rapid symptom relief within 2-4 weeks and does not require dose titration, making it the most convenient alpha-blocker option 2
• Terazosin is equally effective but requires dose titration (starting at 1 mg, increasing to 2 mg, then 5-10 mg over 10 days) and carries higher risk of orthostatic hypotension and dizziness 1, 2, 3
• Both medications work by relaxing prostatic smooth muscle, reducing the dynamic component of bladder outlet obstruction 4

Choose alfuzosin over terazosin in most patients 2

• Alfuzosin has comparable efficacy to terazosin but superior tolerability profile 1, 2
• Terazosin requires careful dose titration and monitoring for blood pressure effects, particularly in elderly patients or those with cardiovascular comorbidities 2, 3
• If the patient has concurrent hypertension requiring treatment, terazosin may provide dual benefit, but the cardiovascular side effects (dizziness, postural hypotension, asthenia) are significantly more common than with alfuzosin 3

---

When to Add or Choose Finasteride

Add finasteride only when prostate enlargement is documented (>30-40cc) or PSA is elevated 2, 4

• Finasteride works by shrinking the prostate over 6-12 months and is ineffective in small prostates 2, 5
• Do not use finasteride as monotherapy for immediate symptom relief—it takes 6-12 months to show benefit and is less effective than alpha-blockers for symptom improvement 5, 6, 7, 3
• Finasteride provides no additional benefit over placebo in men with small prostates (<30cc) 6, 3

Finasteride is indicated for long-term disease progression prevention in men with enlarged prostates 2, 3

• Reduces risk of acute urinary retention by 57% and need for BPH-related surgery by 48% over 2-4 years when combined with alpha-blockers 2
• As monotherapy, finasteride significantly reduces surgical intervention risk compared to placebo, but only in men with prostates >40cc 3

---

Decision Algorithm Based on Clinical Factors

Prostate Size <30cc:

• Start alfuzosin monotherapy 2, 4
• Finasteride provides no benefit in small prostates 2, 6, 3
• Terazosin is an alternative if alfuzosin is unavailable, but requires dose titration 2

Prostate Size 30-40cc (Medium):

• Start alfuzosin, then add finasteride if symptoms persist after 4-12 weeks 2, 3
• Combination therapy improves symptoms better than alpha-blocker monotherapy in medium-sized prostates 3

Prostate Size >40cc (Large):

• Start combination therapy (alfuzosin + finasteride) immediately 2, 3
• Combination therapy is superior to monotherapy for preventing symptom progression in large prostates 2, 3
• If starting with monotherapy, use alfuzosin first for rapid symptom relief, then add finasteride at 4-12 weeks 2

Blood Pressure Considerations:

• Normotensive or well-controlled hypertension: Choose alfuzosin 2
• Uncontrolled hypertension requiring additional antihypertensive: Consider terazosin for dual benefit, but monitor closely for orthostatic hypotension and dizziness 3
• History of orthostatic hypotension or falls: Avoid terazosin; use alfuzosin 2, 3

Symptom Severity (IPSS/AUA Score):

• Mild symptoms (IPSS <8): Watchful waiting with lifestyle modifications 1
• Moderate-to-severe symptoms (IPSS ≥8): Start alpha-blocker immediately 1, 2
• Symptom severity alone does not determine choice between alpha-blockers or finasteride—prostate size is the critical factor 2, 6, 3

---

Critical Pitfalls to Avoid

Never prescribe finasteride without documented prostate enlargement 2, 6, 3

• Finasteride is ineffective in small prostates and provides no benefit over placebo in men with prostates <30cc 6, 3
• Always measure prostate size (via DRE, ultrasound, or PSA as proxy) before prescribing finasteride 1, 2

Never use finasteride as monotherapy for immediate symptom relief 2, 5, 3

• Finasteride takes 6-12 months to work and is significantly less effective than alpha-blockers for symptom improvement 5, 6, 7
• Terazosin improves symptoms 3.93 points at 3 months versus finasteride's 1.38 points 5
• Peak flow rate increases 2.13 ml/s with terazosin versus 0.55 ml/s with finasteride at 3 months 5

Do not overlook cardiovascular side effects with terazosin 2, 3

• Terazosin significantly increases risk of dizziness, postural hypotension, and asthenia compared to finasteride or alfuzosin 3
• Requires dose titration starting at 1 mg for 3 days, then 2 mg for 7 days, then 5 mg daily 1, 5

Do not assume combination therapy is always superior 3

• Combination therapy (finasteride + alpha-blocker) improves symptoms equally to alpha-blocker monotherapy in men with small prostates (<25cc) 3
• Combination therapy provides additional benefit only in medium (25-40cc) or large prostates (≥40cc) 3

---

Sexual Function Considerations

Finasteride increases risk of sexual dysfunction 3, 8

• Increased risk of impotence, erectile dysfunction, decreased libido, and ejaculation disorder versus placebo 3
• Sexual dysfunction occurs in 3-10% of men on finasteride monotherapy 8

Terazosin has lower rates of ejaculatory dysfunction than other alpha-blockers 8

• Ejaculatory dysfunction occurs in 0-1% with terazosin versus 10% with tamsulosin 8
• However, terazosin has higher cardiovascular side effects (dizziness, postural hypotension) than finasteride 3

---

Follow-Up and Monitoring

Evaluate response at 4-12 weeks after initiating alpha-blocker therapy 2, 4

• Use validated questionnaires (IPSS/AUA-SI) to objectively assess symptom improvement 2, 4
• Measure post-void residual if initial PVR was elevated 2

If adding finasteride, reassess at 6-12 months 2, 5

• Finasteride requires 6-12 months to demonstrate full benefit on prostate volume reduction 2, 5
• At 6 months, finasteride reduces prostate volume by 4.57 ml versus 0.17 ml at 3 months 5